In a human clinical trial, although mTOR-i showed a favorable trend of ASD symptoms ( Mizuguchi et al., 2019 ), evidence for cognition and psychiatric comorbidity improvement with mTOR-i is lacking.
← all excerpts
Extension of microglial activation is associated with epilepsy and cognitive dysfunction in Tuberous sclerosis complex: A TSPO-PET study.
1
—
—